Pneumococcal vaccine is under clinical development by CanSino Biologics and currently in Phase I for Streptococcal Pneumonia. According to GlobalData, Phase I drugs for Streptococcal Pneumonia have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pneumococcal vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pneumococcal vaccine overview
Protein-based pneumococcal vaccine is under development for the prevention of streptococcal pneumonia infections. The therapeutic candidate is a serotype-independent protein-based pneumococcal vaccine. It is administered through intramuscular route.
CanSino Biologics overview
CanSino Biologics is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus; MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children; and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation, and protein structure design and recombinant technology to develop vaccines. It works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.
For a complete picture of Pneumococcal vaccine’s drug-specific PTSR and LoA scores, buy the report here.